| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 2837 | 2019 |
| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2331 | 2019 |
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1354 | 2019 |
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of … D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu Journal of clinical oncology 22 (1), 77-85, 2004 | 999 | 2004 |
| Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open … T Powles, ER Plimack, D Soulières, T Waddell, V Stus, R Gafanov, ... The Lancet Oncology 21 (12), 1563-1573, 2020 | 609 | 2020 |
| Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer C Butts, N Murray, A Maksymiuk, G Goss, E Marshall, D Soulières, ... Journal of Clinical Oncology 23 (27), 6674-6681, 2005 | 548 | 2005 |
| Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma C Fakhry, Q Zhang, PF Nguyen-Tan, D Rosenthal, A El-Naggar, ... Journal of clinical oncology 32 (30), 3365, 2014 | 527 | 2014 |
| Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy … PF Nguyen-Tan, Q Zhang, KK Ang, RS Weber, DI Rosenthal, D Soulieres, ... Journal of Clinical Oncology 32 (34), 3858, 2014 | 486 | 2014 |
| Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck JSW Stewart, EEW Cohen, L Licitra, CML Van Herpen, C Khorprasert, ... Journal of clinical oncology 27 (11), 1864-1871, 2009 | 435 | 2009 |
| HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum R Perez-Soler, JP Delord, A Halpern, K Kelly, J Krueger, BM Sureda, ... The oncologist 10 (5), 345-356, 2005 | 387 | 2005 |
| Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells RH Vonderheide, PM LoRusso, M Khalil, EM Gartner, D Khaira, ... Clinical Cancer Research 16 (13), 3485-3494, 2010 | 357 | 2010 |
| Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective study J Porter, R Galanello, G Saglio, EJ Neufeld, E Vichinsky, MD Cappellini, ... European journal of haematology 80 (2), 168-176, 2008 | 313 | 2008 |
| Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label … C Butts, A Maksymiuk, G Goss, D Soulieres, E Marshall, Y Cormier, ... Journal of cancer research and clinical oncology 137, 1337-1342, 2011 | 222 | 2011 |
| Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects C Kollmannsberger, D Soulieres, R Wong, A Scalera, R Gaspo, ... Canadian Urological Association Journal 1 (2 Suppl), S41, 2007 | 221 | 2007 |
| Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases MC Heinrich, H Joensuu, GD Demetri, CL Corless, J Apperley, ... Clinical Cancer Research 14 (9), 2717-2725, 2008 | 218 | 2008 |
| Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind … D Soulières, S Faivre, R Mesía, É Remenár, SH Li, A Karpenko, ... The Lancet Oncology 18 (3), 323-335, 2017 | 208 | 2017 |
| Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment ME Blackstein, JY Blay, C Corless, DK Driman, R Riddell, D Soulières, ... Canadian Journal of Gastroenterology and Hepatology 20, 157-163, 2006 | 202 | 2006 |
| Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis L Paz‐Ares, D Soulières, I Melezínek, J Moecks, L Keil, T Mok, R Rosell, ... Journal of cellular and molecular medicine 14 (1‐2), 51-69, 2010 | 200 | 2010 |
| Liver iron quantification with MR imaging: a primer for radiologists R Labranche, G Gilbert, M Cerny, KN Vu, D Soulières, D Olivié, JS Billiard, ... Radiographics 38 (2), 392-412, 2018 | 177 | 2018 |
| Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II … LL Siu, D Soulieres, EX Chen, GR Pond, SF Chin, P Francis, L Harvey, ... Journal of Clinical Oncology 25 (16), 2178-2183, 2007 | 164 | 2007 |
